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Abstract 
Background 
Apolipoprotein B (APOB) is an integral component of the chylomicron and the atherogenic 
lipoproteins LDL and Lp(a). Exon 26 of the APOB pre-mRNA is unusually long at 7,572 nt 
and is constitutively spliced. It is also subject to RNA editing in the intestine, which 
generates a shortened isoform, APOB48, assembled exclusively into chylomicrons. Due to its 
length, exon 26 contains multiple pseudo splice sites which are not spliced, but which 
conform to the degenerate splice site consensus. 
Results 
We demonstrate that these pseudo splice sites are repressed by multiple, tandem splicing 
silencers distributed along the length of exon 26. The distribution of these elements appears 
to be heterogeneous, with a greater frequency in the middle 4,800 nt of the exon. 
Conclusion 
Repression of these splice sites is key to maintaining the integrity of exon 26 during RNA 
splicing and therefore the correct expression of both isoforms of APOB. 
Keywords 
Apolipoprotein B, RNA splicing, Splicing regulation, Splice sites, Splicing silencers 
Background 
Apolipoprotein B (APOB) is a component of the LDL, Lp(a) and chylomicron lipoprotein 
particles [1]. The full-length APOB100 isoform is mainly synthesized in the liver and is 
assembled into LDL and Lp(a). The pre-mRNA is subject to intestine-specific RNA editing 
by a complex known as the editosome, which includes a catalytic subunit, APOBEC-1, and 
several auxiliary factors. Editing occurs in exon 26 at position 6666 of the mRNA converting 
a C to a U, generating a premature termination codon (PTC), and producing a C-terminal 
truncated isoform, APOB48. This isoform is assembled into the chylomicron particle and is 
unable to bind the LDL receptor [2]. The constitutively spliced exon 26 of APOB is also 
unusual in that it is 7,572 nt long, far longer than the mean length of exons in the genome at 
145 nt [3]. 
Pre-mRNA contains sequence elements defining the 5′ and 3′ ends of introns and the branch 
point. In mammals, the consensus sequences of these elements are highly degenerate [4]. As 
a result, matches to these consensus sequences are highly prevalent throughout the genome 
[5] and outnumber genuine splice sites by an order of magnitude in the human HPRT gene 
[6]. These pseudo splice sites are not normally employed in splicing. How the spliceosome is 
able to differentiate the few genuine splice sites from numerous pseudo splice sites is as yet 
unclear. 
Other sequences within the pre-mRNA have been suggested to influence the choice between 
pseudo splice sites and genuine splice sites to allow accurate and reproducible splicing at the 
latter. Exonic and intronic splicing enhancer sequences (ESE and ISE, respectively) have 
been characterized, and in general these act by binding SR proteins which interact with the 
spliceosome to favour the use of particular splice sites [7-9]. Intronic and exonic splicing 
silencer sequences (ISS and ESS, respectively), which discourage the use of particular splice 
sites, have also been identified on functional and bioinformatic grounds [5,8,10]. Silencing 
elements bind silencing factors such as hnRNP A1 [11], polypyrimidine tract binding protein 
[12] and hnRNP H [13]. The balance between enhancing factors (e.g. SF2) and silencing 
factors (e.g. hnRNP A1) determines the selection of splice sites and alternative splicing 
[14,15]. 
Most of the pseudo splice sites in the human genome reside in introns, by virtue of their long 
lengths [5,6]. Long exons such as APOB exon 26, also contain many pseudo splice sites (vide 
infra). Correctly orientated pseudo 3′ and 5′ splice sites should trigger exon definition and 
erroneous splicing within the exon 26 sequence [16]. Alternatively, the genuine splice sites 
could be identified via a process of intron definition. This relies on the recognition of 5′ and 
3′ splice site pairs over short introns <100 nt in Drosophila [17]. In human nuclear extracts 
and in HeLa cells, intron definition appears to operate below a threshold of 200–250 nt [18]. 
Intron definition, therefore, cannot easily explain the splicing of APOB exon 26 as the 
upstream intron Y and the downstream intron Z are too long at 506 and 403 nt respectively. 
APOB exon 26 provides a crucial test case for the hypothesis that the configuration of ESE 
and ESS within the pre-mRNA is important for the accurate and reproducible splicing of long 
exons. 
Results and discussion 
APOB exon 26 contains many pseudo splice sites 
In order to assess the number of pseudo splice sites within APOB exon 26, we scanned the 
genomic sequence of APOB for matches to the 5′ and 3′ splice sites consensus sequences 
using the position score matrix of Shapiro and Senapathy [4]. A higher score out of 100 
indicates a stronger splice site, and provides an estimate of the likelihood of a sequence being 
identified as an exon boundary and utilised in splicing. The genuine splice sites delineating 
the internal exons 2–28 were identified (Additional file 1: Table S1). The weakest 5′ splice 
site was that of exon 27 (score: 63.5) and the weakest 3′ splice site was that of exon 20 
(score: 74.7). Using 63.5 and 74.7 respectively as the thresholds for the search, 54 5′ splice 
sites with scores ≥63.5 and 103 3′ splice sites with scores ≥74.7 were identified within the 
sequence of APOB exon 26 (Figure 1). 
Figure 1 Shapiro and Senapathy [4] scores for pseudo splice sites scoring higher than 
the lowest-scoring genuine APOB splice sites. The dotted lines show the scores of the 
genuine splice sites flanking exon 26. (A) Scores of 5′ splice sites (ordinate) plotted against 
position in exon 26 (abscissa). (B) Scores of 3′ splice sites (ordinate) plotted against position 
of the in exon 26 (abscissa). The arrow indicates the pseudo splice site that is used in the 
alternative splicing event identified in Figure 6. (C) Table of positions and Shapiro and 
Senapathy scores of pseudo 5′ splice sites in exon 26 scoring higher than the native 5′ splice 
site at position 7572. (D) Table of positions and Shapiro and Senapathy scores of pseudo 3′ 
splice sites in exon 26 scoring higher than the native 3′ splice site at position 1. The asterisk 
indicates the pseudo splice site that is used in the alternative splicing event identified in 
Figure 6. 
The 3′ splice site flanking exon 26 scored 83.2 and the 5′ splice site scored 86.5 (combined 
score 169.7). Using the exon 26 flanking scores of 83.2 and 86.5 as thresholds, 32 3′ splice 
sites and two 5′ splice sites within exon 26 were identified as closer matches to the consensus 
with higher scores than the genuine splice sites flanking exon 26. On theoretical grounds, 
therefore, each of these pseudo splice sites could be used in preference to the genuine splice 
sites, generating two possible 3′ shortened alternatives combining the 5′ pseudo splice sites 
with the 3′ splice site flanking exon 27, and 32 possible 5′ shortened alternatives combining 
the 3′ pseudo splice sites with the 5′ splice site flanking exon 25. 
A search was also made for plausible pseudo-exons within the length of exon 26 using this 
subset of high-scoring pseudo splice sites. These were defined as sequences bounded by 3′ 
and 5′ pseudo splice sites in the right orientation, with lengths of 39–374 bp, these being the 
range of lengths for the other APOB internal exons. Using these criteria at least 3 alternative 
pseudo-exons could be identified that contain pseudo splice sites that are a better fit to the 
consensus than the genuine splice sites, and which on these bioinformatic criteria are more 
plausible exons than exon 26 itself. 
Using an alternative method to identify splice sites, Maximum Entropy Modelling (see 
Additional file 2: Table S2) of the same region identified five 3′ splice sites and one 
alternative 5′ splice site within exon 26 which score higher than the native 3′ and 5′ splice 
sites [19]. Again using the same criteria, one strong pseudo-exon of 143 bp, with an 
appropriately positioned high scoring branch site was identified (position 4906–5048) [20]. 
Both these methods therefore identify plausible pseudo-exons which should in theory be 
spliced into the APOB mRNA instead of the actual exon 26. 
APOB exon 26 contains multiple silencing sequences along its length 
We hypothesized that ESS might be responsible for silencing the pseudo splice sites, with 
two possible architectures for ESS in exon 26. Firstly, a single or a few strong ESS sequences 
might exist which are able to influence large areas of exon 26, similar to hnRNP A1. This is 
able to bind to high affinity sites, cooperatively bind, propagate along an exon, and 
antagonize SR protein function [21]. In this context it should be noted that exon 26 contains 
sequences that resemble consensus high-affinity hnRNP A1 sites [22] such as 2666–2671 
(UAGAGU – found in construct 7 of Figure 2B) and 4114–4119 (UAGGGA – found in 
construct 11 of Figure 2B). Secondly, exon 26 might contain multiple ESS distributed along 
the length of the exon. 
Figure 2 Structure of the DNA ligase III splicing reporter and in vitro splicing assay of 
exon 26 sequences. (A) Top Schematic showing the genomic structure of APOB exon 26 and 
adjacent exons. Boxes represent exons, the lines interconnecting exons represent introns. 
Numbers above exons and introns represent lengths of the respective elements in nucleotides. 
Exon 26 is divided into 400 nt fragments labelled 1 to 18. Note that fragment 19 is shorter 
than fragments 1–18 at 372 nt. Bottom shows fragment 5 in position at the 3′ end of the DNA 
ligase III splicing reporter, replacing the native ESS. (B) In vitro splicing of A constructs: 
10% PAGE shown. Lanes M = pBR322-MspI digest marker; Cß = DNA ligase III C-ß 
construct without ESS; I3+4 = DNA ligase III C-ß with IGF-I exons 3 and 4 tagged to 3′ end; 
1–19 = fragment 1 to 19 constructs. Adjacent cartoons show identity of bands. Note that the 
migration of the splicing intermediates of the DNA ligase III C-ß reporter is characteristically 
retarded on this high percentage gel. (C) Graph showing relative splicing efficiency of 
constructs, normalised to 100% = splicing efficiency of DNA ligase III C-ß construct without 
ESS. 
The length of exon 26 makes it difficult to test for the existence of ESE and ESS in exon 26 
in their native context. Therefore, we turned to a heterologous splicing reporter, DNA ligase 
III. This two-exon construct contains a C exon and an alternatively spliced ß exon which is 
controlled by an ESS within the ß exon. Deletion of the ESS allows C to splice to ß 
efficiently in vitro [23]. Candidate sequences derived from exon 26 were therefore cloned at 
the 3′ end of the ß exon, replacing the native ESS, and these constructs were transcribed and 
tested for splicing in vitro (Figure 2A). Suppression of C-ß splicing indicates presence of ESS 
activity within the candidate sequence. 
Figure 2B shows the results of testing non-overlapping 400 nt fragments derived from exon 
26 in this system. In this system DNA ligase III C-ß splices efficiently, as does a control 
construct containing 339 nt of IGF-I exons 3 and 4, tagged to the 3′ end of DNA ligase III C-
ß (see lanes Cß and I3+4). However, tagging 376–400 nt fragments of exon 26 causes 
silencing of splicing of the C-ß intron (lanes 1–19), with variable silencing activity – compare 
lanes 1–4, 17, 18 with lanes 5–16, 19. Silencing activity appears to be strongest in the middle 
4800 nt of sequence corresponding to fragments 5–16. 
We conclude, therefore, that the sequence of exon 26 contains splicing silencing activity 
throughout its length, but that this activity is heterogeneously distributed. There is no 
evidence of a single super-ESS in exon 26, for example centered around the potential high-
affinity hnRNP A1 sites. 
Microarchitecture of ESS in exon 26 
In order to further investigate the distribution of ESS in exon 26, overlapping 25 nt sequences 
derived from fragment 1 and from fragment 6 were tested using the DNA ligase III in vitro 
splicing system. We selected fragment 1 and fragment 6 as exemplars of relatively well-
spliced and relatively silenced fragments respectively. Moreover, as fragment 6 contains the 
RNA editing site, we wished to see if silencing activity was related to the RNA editing 
activity. 
Figure 3A shows the result of testing these constructs, made with sequences derived from 
fragment 1. At this resolution, there is a heterogeneous distribution of ESS activity, with 
certain sequences such as 65–89 showing silencing better than the native ESS of DNA ligase 
III, REP and other sequences such as 113–137 showing no significant effects on splicing 
(Figure 3B). Identically spliced mRNAs appear as different sized bands in the lower parts of 
Figures 3A and 4A. This is likely to represent variable degrees of exonuclease degradation to 
which mRNAs are susceptible in the nuclear extract used for the assay. 
Figure 3 Microarchitecture of ESS activity in exon 26 sequences derived from fragment 
1. (A) In vitro splicing assay of DNA ligase III C-ß splicing reporter, tagged with 25-mers 
derived from fragment 1 (1 hour splicing at 30°C). 10% PAGE shown. Lanes Cß = DNA 
ligase III C-ß construct without ESS; Cß ex27 1–25 = Cß + nt 1–25 of exon 27; Cß REP = Cß 
+ native ESS; Cß IGF-I ex3 1–25 = Cß + nt 1–25 of exon 3 from IGF-I; DL3 Cß ex 26 lanes 
= nts of exon 26 shown. Adjacent cartoons show identity of bands. (B) Quantification of 
splicing efficiency, normalised to DNA ligase III C-ß reporter. Bars show splicing efficiency 
from n=4 experiments with DNA ligase III C-ß = 100%. Error bars show S.E.M. Overall one-
way ANOVA shows p <0.0001. Comparison to DNA ligase III C-ß for each construct by 
Bonferroni’s multiple comparison test: statistically significant differences from efficiency of 
DNA ligase III C-ß splicing shown by *= p <0.01, **= p <0.001. 
Figure 4 Microarchitecture of ESS activity in exon 26 sequences derived from fragment 
6. (A) In vitro splicing assay of DNA ligase III C-ß splicing reporter, tagged with 25-mers 
derived from fragment 6 (1 hour splicing at 30°C). 10% PAGE shown. Lanes Cß = DNA 
ligase III C-ß construct without ESS; Cß ex27 1–25 = Cß + nt 1–25 of exon 27; Cß REP = Cß 
+ native ESS; Cß IGF-I ex3 1–25 = Cß + nt 1–25 of exon 3 from IGF-I; DL3 Cß ex 26 lanes 
= nts of exon 26 tested are shown above each lane; lane 2319–2343 encompasses the RNA 
editing site and mooring sequence (ED); ED sequence mutations T9A, T9C, A11C, G15C, 
A19T shown in right-hand five lanes. Adjacent cartoons show identity of bands. (B) 
Quantification of splicing efficiency, normalised to DNA ligase III C-ß reporter. Bars show 
splicing efficiency from n=4 experiments with DNA ligase III C-ß = 100%. Error bars show 
S.E.M. Overall one-way ANOVA shows p <0.0001. Comparison to DNA ligase III C-ß for 
each construct by Bonferroni’s multiple comparison test: statistically significant differences 
from efficiency of DNA ligase III C-ß splicing shown by *= p <0.01, **= p <0.001. 
Figure 4 shows the result of testing constructs made with sequences derived from fragment 6. 
In contrast to the fragment 1 sequences, the fragment 6 sequences show less heterogeneity 
with most sequences tested showing ESS activity (see Figure 4A and 4B). We conclude, 
therefore, that exon 26 contains multiple ESS sequences along its length in a heterogeneous 
distribution. More frequent silencing activity is seen with the 25-mers derived from fragment 
6 than fragment 1, consistent with the greater silencing activity of fragment 6 compared to 
fragment 1. 
ESS identified by the DNA ligase III C-ß reporter also silence the Hß∆6 
reporter 
In order to ensure that the ESS activity was not dependent on the splicing reporter, key 
sequences were also tested in the ß-globin splicing reporter Hß∆6 [23,24]. In this different 
context, the 25-mers 65–89 and 2319–2343 ED were also able to repress Hß∆6 splicing by 
~50%, whereas the neutral sequence 161–185 did not significantly repress splicing (Figure 
5). 
Figure 5 Activity of key ESS sequences in the context of Hß∆6. (a) The indicated 
sequences from exon 26 were cloned into the AccI site of exon 2 and tested for in vitro 
splicing activity (2 hour incubation, 30°C). 5% PAGE shown. Adjacent cartoons show 
identity of bands. (b) Quantification of splicing efficiency, normalised to Hß∆6 reporter. The 
bars show splicing efficiency, normalised to Hß∆6 for n=9 experiments, error bars show 
S.E.M. Overall one-way ANOVA shows p <0.0001. Comparison to Hß∆6 splicing efficiency 
for each construct by Bonferroni’s multiple comparison test: statistically significant 
differences shown by **= p <0.001. 
The sequence requirements of RNA editing are distinct from ESS activity 
RNA editing of APOB is dependent on an 11 nt mooring sequence 3′ to the RNA editing site 
itself, which represents a binding site for the editosome [25]. The sequence spanning the 
RNA editing site and mooring sequence (ED) shows ESS activity (see Figure 4A, lane 2319–
2343 ED). As RNA editing and splicing are linked [26] and as both processes may share 
common components, such as KSRP [27] and CUGBP2 [28], we wondered whether the 
silencing activity of ED might be related to its ability to support RNA editing. To this end, 
several point mutations were constructed in ED, three of which are known to knock out RNA 
editing (T9A, T9C, A11C), one of which is neutral with respect to RNA editing (G15C), and 
one of which is intermediate in reducing RNA editing activity (A19T) [28]. These constructs 
were tested for splicing activity (see Figure 4A, right-hand 5 lanes). The mutations did not 
affect the silencing activity of ED, suggesting that the sequence requirements of RNA editing 
are distinct from ESS activity and that perhaps different factors are responsible for silencing 
activity vis-à-vis RNA editing. 
Antisense oligonucleotide blockade of ESS causes alternative splicing of 
APOB 
To investigate the role of these ESS elements in vivo, we turned to 2′-O-methyl antisense 
oligonucleotides (ASOs), which can direct alternative splicing by binding to splice sites or 
regulatory elements [29,30]. These ASOs were targeted at identified ESS, namely elements 
66–89, 97–121, 129–153, 2319–2343 ED (Figure 6: labelled - respectively). We also made an 
ASO targeted to a neutral region, 193–217 (labelled), and a negative control ASO which did 
not match any sequences within APOB. These ASOs were transfected into HepG2 cells, 
which synthesize and secrete APOB. The splicing of APOB exon 26 was assessed by RT-
PCR [30]. 
Figure 6 Antisense oligonucleotides directed against identified ESS elements cause 
alternative splicing of APOB in HepG2 cells. In lanes 1 and 2 the cells were not transfected 
with ASOs. The –RT control PCR (lane 1) was performed without reverse transcriptase. In 
lane 3, the cells were transfected with negative control ASO at 500 nM. Lanes 4–13 were 
transfected with the indicated ASOs at 125 nM each; the total concentration of ASO was 
adjusted to 500 nM with negative control ASO. Cells were incubated for 48 hours and RT-
PCR was carried out on the total RNA extracted from these cells with oligonucleotides 
annealing to the adjacent exons 25 and 27. The positions of the bands corresponding to the 
APOB mRNA species with constitutive exon 26 inclusion (top), pseudo 3′ splice site 
activation (middle) and skipping of exon 26 (bottom) are indicated on the right side. 
Fragment lengths in bp of the markers are indicated on the left side. 
As shown in Figure 6, targeting ASOs individually to each ESS did not cause significant 
alternative splicing (compare lanes 2 and 3 with lanes 4–7). Targeting the neutral sequence 
193–217 did not alter splicing (compare lanes 2 and 3 with lane 8). Targeting another neutral 
sequence 2191–2215 did not alter splicing (Additional file 3: Figure S1: compare lane 6 with 
lane 2). However, when mixtures of ASOs were combined, especially when ESS 66–89, 97–
121 and 129–153 were targeted simultaneously, we saw significant alternative splicing of 
APOB to two alternative isoforms (compare lanes 2 and 3 with lanes 9–13): one in which 
exon 26 was skipped to join exons 25 and 27 together; and one in which a pseudo 3′ splice 
site (Shapiro and Senapathy score 90.4 and Maximum Entropy Modelling score 10.04) was 
selected at position 7048 within exon 26 (see also Figure 1B – this splice site is indicated 
with the arrow). Maximum Entropy Modelling ranks this pseudo 3′ site as the highest scoring 
and strongest 3′ site within APOB exon 26 (Additional file 2: Table S2), in comparison to the 
native 3′ splice site (score 7.68). This therefore implies that: (1) these elements have a 
function in suppressing pseudo splice site selection in vivo; and (2) that these elements have 
functional redundancy. 
While the splice site strength of this cryptically activated 3′ splice site is higher than the 
native 3′ splice site it is unclear why a group of ESS approximately 7,000 nt upstream might 
be involved in repressing this pseudo splice site. We may speculate that disruption of exonic 
silencers allows more efficient aggregation of splicing factors around cryptic splice sites 
further downstream, thereby increasing the kinetics of spliceosome assembly and allowing 
minor isoforms to become apparent. The other possibility is that interference with ESS allows 
silencing protein activity to become more influential at the constitutive 3′ splice site. Other 
methodological explanations include the possibility that pseudo splice sites nearer the ESS 
sites are selected which would give significantly larger products which were not amplified 
efficiently by the PCR in comparison to the shorter transcripts, or that could not be 
distinguished from constitutively spliced transcript by gel electrophoresis under the 
conditions which we used. 
Computational identification of ESS is less specific and sensitive than splicing 
assays 
Experimental and computational models, such as FAS-ESS hexamers and putative ESS 
(PESS) octamers as defined by Zhang and Chasin [8], can be used to predict ESS sites in 
exon 26 and which may then be compared with sites identified in our assay. FAS-ESS 
hexamers appear to occur along the exon 26 sequence (Additional file 4: Figure S2), but there 
does not appear to be any bias towards more frequent appearances within the middle of the 
exon as noted in our assay. We found that there was a variable correlation of FAS-ESS 
hexamers within 25mer ESS identified in our assays (Additional file 5: Figure S3 and 
Additional file 6: Figure S4) but overall these appear to be less sensitive (50%) and less 
specific (40%) than the in vitro splicing assay. A similar picture was again apparent with the 
PESS matches (Additional file 5: Figure S3 and Additional file 6: Figure S4). 
It has also been suggested that the distribution of splicing enhancer sequences can influence 
the use of genuine splice sites over pseudo splice sites. We therefore searched for ESE 
sequences within exon 26, using tools derived from computational and experimental 
modeling [7,8,31-33] to see if there might be such a bias in the distribution of ESE. However, 
putative ESE were noted all along the length of the exon and do not appear to have a bias for 
the ends of the exons, in keeping with other similar studies [34], suggesting that ESE do not 
appear to contribute to the selection of genuine splice sites in exon 26. This is further 
confirmed by the fact that we did not detect any significant enhancement of reporter splicing 
by the tested sequences. 
Secondary structure 
A prediction of the secondary structure folding of APOB exon 26 pre-mRNA and its flanking 
introns, utilising the mfold web server (see Additional file 7: Table S3) shows that Region 
A6, which has inherently higher silencing activity compared with region A1, is predicted to 
contain more secondary structure [35]. In particular, the ESS containing the editing site, 
targeted by ASO (2319–2343), contains a high degree of secondary structure (76% of the 
sequence predicted to be base-paired). Work by Hiller and colleagues [36] suggests that 
splicing elements are more effective when they are in single-stranded conformations, which 
does not fit with our observation that the A6 region (with the highest density of ESSs) is 
predicted to form strong secondary structures, and more so than the A1 region which has a 
lower density of ESSs. Moreover, as the formation of secondary structure by a particular 
sequence is highly dependent on the context of its neighbouring sequences, it is unclear how 
the ESSs, if they are working primarily by means of mechanisms dependent on the formation 
of secondary structure, could inhibit the splicing of the two different heterologous splicing 
reporters used here. For these reasons we believe that secondary structure may not be a key 
influence in pseudo splice site silencing in exon 26. 
Nonsense-mediated decay 
In addition to regulation of splicing, other mechanisms have been proposed to ensure that 
mature mRNAs have been accurately spliced. Nonsense-mediated decay (NMD) is 
conceivably a mechanism for suppressing PTC-containing mRNAs generated by aberrant 
splicing to cryptic splice sites, and is in some cases a mechanism for regulation of protein 
expression [37]. However, despite the fact that RNA editing generates a PTC in the middle of 
exon 26, edited APOB mRNA appears to not be subject to NMD, nor is a PTC-containing 
APOB mRNA isoform skipping exon 27 [30]. In the case of exon 26, the binding of the 
APOBEC-1 complementation factor (ACF), a component of the editosome, is important in 
protecting the edited RNA from NMD [38]. Further, out of the 37 alternative isoforms 
generated by use of high-scoring pseudo splice sites in exon 26, 16 are predicted to splice in-
frame and do not contain PTCs. Therefore, NMD is not a plausible mechanism for policing 
the selection of splice sites in APOB splicing. 
Conclusions 
The splicing of RNA requires the accurate selection of genuine splice sites over numerous 
pseudo splice sites, and this is facilitated by additional RNA sequence information in the 
form of splicing enhancers and silencers. Accurate splicing of exon 26 is necessary to ensure 
that APOB is expressed correctly and assembled into the correct lipoprotein particles. 
To our knowledge, this is the first time a partial survey of splicing elements has been carried 
out in a long exon. In most experimentally characterised cases, ESS have been isolated as 
single elements or sometimes bipartite elements of variable length from 5 nt [39] to 119 nt 
[40], usually in the context of alternative splicing. In exon 26, our data demonstrate that there 
exist multiple, tandem ESS, a unique configuration of ESS. We show, in vivo, that blocking 
selected ESS with antisense oligonucleotides triggers the selection of the strongest 3′ pseudo 
splice site within exon 26, i.e. cryptic activation of the pseudo splice site. Although 
constitutive splicing of exon 26 at the native splice sites continues to generate the dominant 
isoform, and the alternative splicing effects are small, we speculate that this may be ascribed 
to poor access of blocking oligonucleotides to the spliceosome and the fact that we have only 
targeted a small number of multiply redundant ESS. This latter notion is supported by the fact 
that blockade is only effective with combinations of ASOs. 
We hypothesize that these multiple ESS may serve to suppress the pseudo splice sites within 
it, and we propose that similar mechanisms may govern the accurate splicing of other long 
exons in the genome. 
Furthermore, it is possible that polymorphisms within the exon 26 sequence, even if 
translationally silent, may perturb these silencers and disturb splicing of exon 26, leading to 
subtle alterations of APOB expression and function which may underlie inter-individual 
differences in lipoprotein levels and function [41,42]. 
Methods 
Computer analysis of sequences 
The Homo sapiens genomic DNA sequence of APOB was obtained from Ensembl (HUGO 
ID: APOB) [43]. The SpliceSiteFinder server was used to scan exon 26 for potential splice 
sites, scored according to the matrices of Shapiro and Senapathy [4,44]. ESEfinder was used 
to scan for potential SR protein binding sites [33,45]. The RESCUE-ESE web server was 
used to scan for putative ESE hexamers [9,46]. The FAS-ESS web server was used to scan 
for putative ESS hexamers [10,47]. The PESx web server was used to scan for putative ESS 
as defined by Zhang and Chasin [8,48]. Maximum Entropy Modelling [19] was additionally 
used to scan exon 26 for potential splice sites. 
Construction of DNA ligase III constructs 
All oligonucleotides were obtained from Sigma-Genosys Ltd., Cambridge, UK. 400 nt 
fragments of exon 26 were amplified from human genomic DNA or HepG2 cDNA, and 
coupled to T7 DNA ligase III C-ß DNA template [49] by overlap-extension PCR [50] 
employing Phusion DNA polymerase (Finnzymes OY, Finland). Sequences were confirmed 
by direct DNA sequencing. T7 DNA ligase III constructs containing 25-mer sequences from 
exon 26 were constructed by PCR employing reverse oligonucleotides containing the reverse-
complement of the desired sequence appended to the 5′ end of the DNA ligase III C-ß 
sequence. Hß∆6 constructs were made by annealing complementary oligonucleotides 
containing the desired 25-nucleotide sequences with 5′-CT and 5′-AG overhangs, and these 
were cloned into the AccI site within the second exon of Hß∆6 [23,24]. Oligonucleotide 
sequences are available on request. 
In vitro analysis of splicing 
Labelled, capped RNA transcripts were generated using the appropriate RNA polymerase 
(Ambion, Inc., Huntingdon, UK), 1 mM 7mG(ppp)G cap structure analogue (NEB, Hitchin, 
UK), 0.5 mM each of ATP, UTP, CTP and 0.05 mM of GTP, and 5–10 µCi [α-32P] GTP 
(Perkin-Elmer LAS Ltd., Beaconsfield, UK) [51]. 20 fmol of labelled RNA was employed in 
in vitro splicing reactions with 10 µl of HeLa nuclear extract (Computer Cell Culture, Mons, 
Belgium) for 1 hour at 30°C (DNA ligase III constructs), 2 hours at 30°C (Hß∆6 constructs) 
or on ice as indicated [52]. Purified spliced RNA was analysed with 5% or 10% urea-PAGE 
(Sequagel, National Diagnostics, Hessle, UK) and autoradiography. Quantification of 
autoradiographs was performed using FujiFilm Image Gauge software version 4.2 (FujiFilm 
Medical Systems, Stamford, CT, USA). 
Antisense oligonucleotide transfection of HepG2 cells 
HepG2 cells were maintained in Minimum Essential Medium with Earle’s salts and 
glutamine, 10% fetal bovine serum (Gibco/Invitrogen, Paisley, UK) at 37°C under 5% CO2. 
2′-O-methyl ASOs were ordered from Dharmacon (Lafayette, CO, USA). The sequences (5′-
3′) of the ASOs were as follows: ASO 65–89 GAUAUUCGAAUCUAGAAAUUUGUGG; 
ASO 97–121 UUGUUUCCAAGUUUUUCUACAUGAC; ASO 129–153 
CAUCGAAUAUUAGUAAACCUUUUGA; ASO 2319–2343 
CUUUAAAUAUACUGAUCAAAUUGUA; ASO 93–217 
UGCUGUUUCUUUUUGGAGUCCAAAU; negative control ASO 
GGCCGAUCCGUCAGUCCA. 
ASOs were transfected in 12-well plates, with 1 x 106 cells per well, using 2.4 µl 
Lipofectamine 2000 in 200 µl OptiMEM I (Invitrogen) as per the manufacturer’s protocol, 
then incubated for 48 hours before harvesting. Total RNA was isolated from cells using the 
RNeasy Micro kit (Qiagen, Crawley, UK). The RNA concentration was quantified using the 
NanoDrop 1000 (Thermo Scientific, Waltham, MA, USA), and 2.5 µg was reverse-
transcribed using Transcriptor reverse transcriptase (Roche Applied Science, Burgess Hill, 
UK) with an oligo dT15 primer as per the manufacturer’s protocol. 0.25 µl of the cDNA was 
then analysed in an RT-PCR reaction with Exl DNA polymerase (Stratagene, La Jolla, CA, 
USA) and 0.5 µCi [α-32P]-dCTP (Amersham, Little Chalfont, UK) using the following 
primers: forward (exon 25) GCCATCTCGAGAGTTCCAAG and reverse (exon 27) 
GTCACGGTGTGCAAATGTTC according to the manufacturer’s instructions. The PCR 
reaction was then subjected to PAGE on a non-denaturing 6% gel, and autoradiographed. The 
identity of each PCR product of interest was confirmed by excision and sequencing. 
Statistical analysis 
Statistical analysis was performed using Prism version 4.0c (GraphPad Software, Inc., San 
Diego, CA, USA). Comparisons between quantitated datasets were performed using one-way 
ANOVA. Bonferroni’s test was used to analyse the differences in splicing efficiency between 
individual constructs and control constructs. 
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Additional file 1: Table S1 Shapiro and Senapathy [4] scores for the splice sites flanking the 
internal exons 2–28 of APOB. 
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Additional file 2: Table S2 Maximum Entropy Modelling scores [19] for 3′ and 5’ splice 
sites. Only motifs with higher scores than the native splice sites (italics) shown. Branch point 
sequences motifs with appropriate strength (score >70) and positioned within 50 nucleotides 
of a 3′ splice site capable of generating a pseudoexon [20]. 
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Additional file 3: Figure S1 Antisense oligonucleotides directed against identified ESS 
elements of APOB exon 26 in HepG2 cells – additional control oligonucleotide included. In 
lanes 1 and 2 the cells were not transfected with ASOs. The –RT control PCR (lane 1) was 
performed without reverse transcriptase. Lanes 3–6 were transfected with the indicated ASOs 
at 250 nM each. An additional control oligonucleotide targeting a neutral sequence is shown 
in lane 6. Cells were incubated for 48 hours and RT-PCR was carried out on the total RNA 
extracted from these cells with oligonucleotides annealing to the adjacent exons 25 and 27. 
The positions of the bands corresponding to the APOB mRNA species with constitutive exon 
26 inclusion (top), pseudo 3′ splice site activation (middle) and skipping of exon 26 (bottom) 
are indicated on the right side. Fragment lengths in bp of the markers are indicated on the left 
side. 
Additional_file_4 as JPEG 
Additional file 4: Figure S2 Frequency of FAS-ESS hex2 hexamers in the APOB exon 26 
sequence. FAS-ESS hex2 subset refers to those hexamers found at least twice within 
recovered decamers from the FAS-ESS procedure [47]. Hexamers were counted in a non-
overlapping 16 bp windows and normalised to the number of possible hexamers per 16 nt. 
Blue line shows normalised hexamer ratio plotted for each window. Black line shows a 
moving average over 5 windows. 
Additional_file_5 as PDF 
Additional file 5: Figure S3 Computational identification of potential ESS sequences within 
the exon 26 sequence. The exon 26 sequence is shown in black, with numbers above denoting 
the position in exon 26. 25-mers tested in the DNA ligase III reporter system are shown 
below the exon 26 sequence, sequences with ESS activity are denoted by white-on-black text, 
neutral sequences are denoted by black-on-white text. Sequences containing hexamers 
identified by the FAS-ESS server program are in bold [47]. Matches to the PESS sequences 
identified by Zhang and Chasin [8] are underlined. 
Additional_file_6 as PDF 
Additional file 6: Figure S4 Computational identification of potential ESS sequences within 
the exon 26 sequence derived from fragment 6. The exon 26 sequence is shown in black, with 
numbers above denoting the position in exon 26. 25-mers tested in the DNA ligase III 
reporter system are shown below the exon 26 sequence, sequences with ESS activity are 
denoted by white-on-black text, neutral sequences are denoted by black-on-white text. 
Sequences containing hexamers identified by the FAS-ESS server program are in bold [47]. 
Matches to the PESS sequences identified by Zhang and Chasin [8] are underlined. 
Additional_file_7 as DOC 
Additional file 7: Table S3 Degree of base-pairing secondary structure predicted for regions 
of APOB exon 26 using the Mfold web server [35]. These include the native 3′ and 5′ splice 
sites, parts of region A1 (1–281) and A6 (2143–2407) investigated in vitro (see Figure 2 &3) 
and the regions of exon 26 targeted by the ASOs 1–6. Secondary structure was analysed 
using the whole of exon 26 in addition to the entire length of the adjacent introns either side. 
Figures shown are the number of nucleotides predicted to be base-paired using the 4 most 
stable structures predicted (range of ∆G −2245.70 to −2244.2 kcal/mol) Final column gives 
the average number of nucleotides base-paired and the %nucleotides base-paired for the 
given sequences. 
Base-pairing
Region sequence length 1 2 3 4 Average
∆G/ kcal/mol -2245.70 -2245.6 -2245.5 -2244.2
3  splice site (native) -10-10 20 14 14 14 14 14     (70.0%)
5′ splice site (native) 5262 -5583 20 10 10 13 10 10.8  (53.8%)
A1 region 1-281 281 161 167 166 169 165.8 (59.0%)
ASO 1 target 64-89 25 18 14 17 18 16.8   (67.2%)
ASO 2 target 97-121 25 11 6 11 11 9.8     (39.2%)
ASO 3 target 129-153 25 11 13 12 11 11.8   (59.0%)
ASO 5 (neutral) target 193-217 25 16 19 13 16 16     (47.2%)
A6 region 2143-2407 265 167 168 179 182 174   (65.7%)
ASO 4 (ED) target 2319-2343 25 19 19 19 19 19     (76.0%)
ASO 6 (neutral) target 2191-2215 25 8 8 8 8 8       (32.0%)
Position
BPS 3 splice sites 5  splice sites
sequence score sequence score sequence score
1 TCTTTTCATTTTTATGTTAG |GAT 7.68
4855 TGCTCAT 90
4905 AAATTCTCTTTTCTTTTCAG | CCC 8.71
5048 CAA | GT AAGT 10.08
5739 TCTCAAGCTTTCTCTTCCAG | ATT 8.41
6719 TTCATTCTGGGTCTTTCCAG | AGC 8.34
7047 GTTCCATGTCCCATTTACAG | ATC 10.04
7428 TGTCATTCCTTCCTTTCAAG | CAC 7.73
7572 ATG | GT AAGA 9.48
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